What changed
$GSK — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $1.9B | EPS $1.26 vs $1.16 🟢
💡 Consensus expects lingering litigation overhang and slow growth post-Haleon spin-off. Our variant view: earnings power is underappreciated, legal fears are exaggerated, and the company is poised for re-rating toward pharma peer averages.
📉 Reward/risk: 2.55:1
🏢 Business Quality: 7/10 - Industry-leading vaccines and HIV portfolio with strong pipeline, but faces Zantac litigation risk and occasional patent cliffs.
📊 Valuation: cheap - Forward P/E 10.5 (vs. large pharma peers at 14x and GSK's 5-year average 13x), FCF yield ~7%, and EV/EBITDA below sector median,...
🔮 Catalyst: Forthcoming quarterly results (likely within 3 months) confirming strong pipeline execution, and/or favorable Zantac settlement news.
💰 Entry: $52.785, stop $48.0, target $65.0
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/GSK0617